Toll Like Receptor 8 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H1 2020’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders under development targeting Toll Like Receptor 8 (CD288 or TLR8).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope


– The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

– The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

– The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Altimmune Inc

Ascendis Pharma A/S

BioNTech SE

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac AG

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

IngenoVax LLC

Janus Biotherapeutics Inc

Nektar Therapeutics

Seven and Eight Biopharmaceuticals Corp

Shanghai De Novo Pharmatech Co Ltd

Silverback Therapeutics Inc

Vaccex Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) Overview

Toll Like Receptor 8 (CD288 or TLR8) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) Companies Involved in Therapeutics Development

BioNTech AG

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Pfizer Inc

Vivelix Pharmaceuticals Ltd

Toll Like Receptor 8 (CD288 or TLR8) Drug Profiles

854-A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUCPT-8m Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1508052 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + MEDI-9197 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-1001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6742 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9688 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-9200 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INGMM-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-9197 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-262 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8) Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) Product Development Milestones

Featured News & Press Releases

Oct 11, 2018: Gilead to present data on Hepatitis B drug candidate GS-9688 at The Liver Meeting 2018

Jul 03, 2018: Recent Studies Unveil Clues to Using Immunotherapy as Cancer Treatment

Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors

Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting

Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus

Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy

Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer

Jul 16, 2014: Resolve Initiates Phase 2 Clinical Study in SLE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Altimmune Inc, H1 2020

Pipeline by Ascendis Pharma A/S, H1 2020

Pipeline by BioNTech SE, H1 2020

Pipeline by Bolt Biotherapeutics Inc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Curebiotech Inc, H1 2020

Pipeline by Curevac AG, H1 2020

Pipeline by Dynavax Technologies Corp, H1 2020

Pipeline by Eisai Co Ltd, H1 2020

Pipeline by Galderma SA, H1 2020

Pipeline by Gilead Sciences Inc, H1 2020

Pipeline by IngenoVax LLC, H1 2020

Pipeline by Janus Biotherapeutics Inc, H1 2020

Pipeline by Nektar Therapeutics, H1 2020

Pipeline by Seven and Eight Biopharmaceuticals Corp, H1 2020

Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020

Pipeline by Silverback Therapeutics Inc, H1 2020

Pipeline by Vaccex Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports